Veloxis Pharmaceuticals A/S Establishes New Warrant Programme

Company Announcement no. 19/2016

To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 25 August 2016

Veloxis Pharmaceuticals A/S Establishes New Warrant Programme

Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for employees of the Company. Thus, the Board of Directors of the Company has today partly exercised its authorisation pursuant to the Articles of Association.

The purpose of the grant of warrants is to reflect the Company's objective to attract and retain first-rate employees and thus ensure a long-term shareholder value creation. The grant of warrants shall ensure to create - both in the short and in the long run - common interests between employees and the shareholders of the Company.

A total of 4,010,000 warrants are to be awarded, giving the right to subscription of up to 4,010,000 shares each of DKK 0.1. The exercise price is fixed at DKK 1.32.

The warrant holders earn the right to exercise warrants with 1/36 per month as from the date of grant 25 August 2016. Warrants that are not exercised on 25 August 2023 expire automatically.

The issued warrants are estimated to have a total market value of DKK 2.17 million. The market value of the issued warrants is calculated on basis of the Black-Scholes model with a volatility calculated as 52%, an interest level of 0% and a share price of DKK 1.32.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Craig A. Collard

President & CEO          

Phone: +1 919 591 3065         

Email: cac@veloxis.com

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

Vedhæftede filer:

250816 Veloxis Establishes Warrant Programme.pdf